Inquiry Basket
DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-00868 | -- | $-- | Inquiry |
DBCO-(PEG2-VC-PAB-MMAE)2, a specialized drug conjugate employed in targeted cancer therapies, offers a multitude of applications. Here are four key applications:
Targeted Cancer Therapy: DBCO-(PEG2-VC-PAB-MMAE)2 plays a pivotal role in formulating antibody-drug conjugates (ADCs) tailored to zero in on cancer cells with precision. This compound enables the specific delivery of the cytotoxic agent MMAE to cancerous cells, while sparing healthy tissues from harm. Such targeted precision not only enhances therapeutic effectiveness but also mitigates adverse effects, marking a significant advancement in cancer treatment strategies.
Bioconjugation Technology: In the realm of bioconjugation techniques, DBCO-(PEG2-VC-PAB-MMAE)2 emerges as a prominent player, facilitating the linkage of drugs to antibodies or other targeting molecules. The DBCO moiety showcases high reactivity with azide-functionalized molecules, fueling the construction of intricate bioconjugates through the art of click chemistry. This innovative approach propels the development of novel therapeutic agents and diagnostic tools.
Pharmacodynamics Studies: Researchers harness the power of DBCO-(PEG2-VC-PAB-MMAE)2 in delving into the pharmacodynamics and mechanistic underpinnings of cancer therapeutics. By scrutinizing the behavior and efficacy of the conjugate in preclinical models, scientists glean insights into drug delivery kinetics, cellular uptake dynamics, and toxicity profiles.
Immunotherapy Research: DBCO-(PEG2-VC-PAB-MMAE)2 takes center stage in the realm of immunotherapy research, driving the development of cutting-edge combination therapies that marry targeted drug delivery with immune modulation. By conjugating MMAE to antibodies that specifically target immune cells, researchers aspire to bolster anti-tumor immune responses. This innovative amalgamation holds immense potential in enhancing the efficacy of cancer immunotherapies, charting a promising trajectory in the fight against cancer.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
